Drug Search Results
More Filters [+]

Pegamotecan

Alternative Names: pegamotecan
Latest Update: 2012-09-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Enzon
Company Location: CRANFORD NJ 07016
Company CEO: Richard L. Feinstein
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pegamotecan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastrointestinal Cancer|Esophageal Cancer|Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CAM-9011

P2

Terminated

Gastrointestinal Cancer|Esophageal Cancer

None

CAM-9009

P2

Suspended

Sarcoma

None

Recent News Events

Date

Type

Title